(0.00%) 5 187.67 points
(0.44%) 39 056 points
(-0.18%) 16 303 points
(0.38%) $79.29
(-0.32%) $2.18
(-0.23%) $2 316.90
(-0.02%) $27.60
(0.16%) $986.20
(0.05%) $0.931
(0.09%) $10.90
(0.02%) $0.800
(-0.01%) $91.73
Quarter results today
(amc 2024-05-09)
Expected move: +/- 6.70%
@ $8.22
Išleistas: 14 vas. 2024 @ 16:30
Grąža: 23.84%
Ankstesnis signalas: vas. 13 - 16:30
Ankstesnis signalas:
Grąža: -2.26 %
Live Chart Being Loaded With Signals
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients...
Stats | |
---|---|
Šios dienos apimtis | 621 967 |
Vidutinė apimtis | 819 065 |
Rinkos kapitalizacija | 529.44M |
EPS | $0 ( 2024-02-28 ) |
Kita pelno data | ( $-0.190 ) 2024-05-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.88 |
ATR14 | $0.0160 (0.16%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-01 | Novack Jeffrey Adam | Sell | 1 905 | Common Stock |
2024-04-24 | Novack Jeffrey Adam | Sell | 0 | Common Stock |
2024-04-24 | Novack Jeffrey Adam | Sell | 2 385 | Employee Stock Option (right to buy) |
2024-04-24 | Novack Jeffrey Adam | Sell | 2 150 | Employee Stock Option (right to buy) |
2024-05-01 | Jain Abhishek | Sell | 7 371 | Common Stock |
INSIDER POWER |
---|
8.60 |
Last 100 transactions |
Buy: 1 531 623 | Sell: 918 597 |
Tūris Koreliacija
CareDx Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
INFI | 0.962 |
BAND | 0.958 |
NKTR | 0.955 |
FULC | 0.954 |
INGN | 0.953 |
ORGS | 0.953 |
UPLD | 0.949 |
JAGX | 0.941 |
MICS | 0.936 |
GOODM | 0.934 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
TIG | -0.918 |
TYHT | -0.915 |
MYRG | -0.913 |
SGEN | -0.911 |
OPCH | -0.906 |
PPYAU | -0.898 |
APEN | -0.889 |
RELY | -0.889 |
KNBE | -0.882 |
ALTR | -0.88 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
CareDx Inc Koreliacija - Valiuta/Žaliavos
CareDx Inc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $280.32M |
Bruto pelnas: | $175.87M (62.74 %) |
EPS: | $-3.54 |
FY | 2023 |
Pajamos: | $280.32M |
Bruto pelnas: | $175.87M (62.74 %) |
EPS: | $-3.54 |
FY | 2022 |
Pajamos: | $321.79M |
Bruto pelnas: | $209.58M (65.13 %) |
EPS: | $-1.440 |
FY | 2021 |
Pajamos: | $296.40M |
Bruto pelnas: | $199.01M (67.14 %) |
EPS: | $-0.582 |
Financial Reports:
No articles found.
CareDx Inc
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.